Arturo Garcia

The 2026 Colorado survey shows teen cannabis use fell to 10 percent in 2025, down from 21 percent in 2015. Legalization has not increased youth access and may have reduced it, though causation is unclear. Broader trends, including shifting attitudes and rising vaping, highlight a more complex picture beyond this decline.

The DEA has begun a key hearing on reclassifying cannabis from Schedule I to Schedule III, following a recommendation from health authorities. While not legalization, the move could ease research, boost medical use, and reduce tax burdens for companies. The outcome, expected later, may influence global markets and reshape international cannabis policy discussions.

With Independence Day on a weekend this year, that means a whole other set of events on top of the usual Americaness goings-on.

Uruguay hosted Brazil's ANVISA delegation to strengthen cooperation in medicinal cannabis through regulatory discussions, site visits, and stakeholder meetings. Brazil remains a key exporter of cannabis medicines to Uruguay. The visit strengthened bilateral ties, showcased industry innovation, and supported regulatory progress, including Uruguay's new health agency, reinforcing growth and collaboration in the sector.

Virginia's cannabis experience shows that legalization alone does not create a functioning market. Despite legal possession since 2021, consumers lacked legal sales until a regulated system was approved for 2027. The state's slow transition offers lessons for Germany, where access challenges remain. Effective legalization requires supply chains, licenses, businesses, and practical consumer access.

U.S. states with legal recreational cannabis have collected over $28.4 billion in sales taxes, with 2025 reaching a record $4.57 billion. While cannabis revenues fund healthcare, education, and community programs, growth is slowing in mature markets. The report highlights both the economic benefits and challenges of balancing taxation with legal-market competitiveness.

Weekend events sure to lure – not just for whiskey and brewery enthusiasts, but also for the emo and Northern Soul lovers in your life.

The warming of the weather brought with it the return of StocktonCon to the Adventist Health Arena on Saturday -- the event's second session of the year.

Germany's Parliament passed the Statutory Health Insurance Contribution Rate Stabilization Act on July 10th, 2026, changing cannabis reimbursement rules. Around 65,000 patients must first try approved cannabis medicines for six months before flowers or extracts qualify for insurance coverage. Critics argue limited approved options, higher costs, and reduced medical freedom may restrict patient access.

Germany and Switzerland's cannabis reforms suggest regulated access can reduce criminalization without increasing consumption. Germany saw fewer cannabis-related prosecutions, while Swiss pilot programs reported stable or lower use, reduced illegal-market reliance, and improved public health outcomes. Early evidence challenges prohibitionist predictions and supports carefully controlled legalization models focused on safety and regulation.